Location: University of Utrecht (the Netherlands)
Date of establishment: 2008 Duration of contract: 6 years End of furtherance: 2014 Chairholder: Prof. dr. Bas Blaauboer By
establishing and funding an endowed professorship on alternative methods to animal
experimentation at IRAS (the Institute for Risk Assessment Sciences) the
Utrecht University, the Doerenkamp-Zbinden Foundation and the Faculty of
Veterinary Medicine, Utrecht University pursue the common goal to promote the
development of alternative methods exclusively in the field of toxicology and
their implementation into regulations through interdisciplinary research and
education in an international context.
The work of the chair is focusing on the need to
improve the toxicological risk assessment process, thereby acknowledging the
need to reduce and replace the use of animal-based models. This requires a
shift in the paradigm of toxicity testing from a system that is based on
determining apical endpoints (clinical, clinical-chemical and histopathological
parameters) in animal studies towards the interpretation of mechanisms of
toxicity linked to changes in biological pathways in cellular systems. Using
these data as the basis for a quantitative extrapolation from in vitro dose metrics to in vivo exposure scenarios in a
transparent, robust and reliable system will then give improved predictions of
toxicological risk. When cellular systems derived from human tissues are
employed, thus avoiding the problems with interspecies extrapolations, such
systems can be better used for predicting human health risks.
The chair
focuses on the following lines of research:
1. Biotransformation of compounds in human in vitro systems. 2. Use of in vitro models to
study mechanisms of toxicity. 3. Development of QSAR models for the estimation of relevant toxic
endpoints. 4. Development and implementation of PBBK models for the interpretation
of in vitro toxicity data for their
relevance of exposure scenarios. 5. Research in the factors and actors involved in the implementation of
alternative methods in regulatory processes. Information about the chair at the University of Utrecht
can be found at the following link: → http://www.uu.nl/staff/BJBlaauboer/0
Highlighted projects:
- Factors stimulating or obstructing the acceptance and
implementation of the 3rs in the regulatory process.
Approximately 30% of the animal experiments within the
European Union is done to meet regulatory requirements. Regulatory animal
testing is part of the safety and quality testing done prior to the release of
a product or compound onto the market to ensure the safety of humans, animals
or the environment. The requirements prescribe which experiments must be
carried out in order to license and release a compound or product onto the
market. Over the last
decades the heavy reliance on animal experimentation in this area has
encountered serious objections for ethical, scientific and economical reasons.
The new Directive 2011/63/EU, which regulates the protection of animals used
for experimental and other scientific purposes at a European level, stipulates
that alternatives, if available, should be used. The requirements dealing with the registration and
release of products often leave room for regulators to choose the testing
method they perceive as most suitable for the job. But even though the number
of 3R methods has risen sharply over the last decades, regulatory acceptance
and the implementation of alternative methods has not kept pace with the
development of these tests. This means that, even if safety and quality
requirements allow the assessors and industry to use available alternative
methods, they often show a preference for the conventional methods. The acceptance and implementation of alternative
methods proves to be a difficult process that meets with a whole range of
obstacles. This raises the question how regulators and industry
use the discretionary space available to them and which factors influence the
decision-making process preceding regulatory acceptance and implementation of
3R methods models. Although a general study has
been conducted to identify possible factors influencing regulatory and
industries decision making whether or not to accept/implement 3R methods
(Schiffelers et al, 2005), it has become clear that the actual situation
differs per sector/ per product and maybe even per industry. To identify the
actual importance and relative force of these different factors on the
acceptance and implementation of 3R method for regulatory purposes, the
examination of case-studies is needed.
Update: Withing this project a PhD thesis was published in 2016. The entire work is available for download:
>>„ANIMAL TESTING, 3R MODELS AND REGULATORY
ACCEPTANCE - Technology Transition in a Risk-averse Context“<< - Improving quantitative in vitro-in vivo extrapolation by using alternative dose
metrics in vitro
This project aims to
develop an understanding of the dose metric that is required from in vitro toxicity assays to accurately
extrapolate in vitro toxicity data to
in vivo relevant doses. Currently, in vitro toxicity data are expressed as
nominal concentrations in culture medium. However, the use of such
concentrations for quantitative in vitro-in
vivo toxic dose extrapolations may introduce serious uncertainties as these
concentrations are highly dependent on the in
vitro set-up and may not accurately reflect the true toxic potency of the
test chemical. By measuring the nominal, free and internal cell concentration
of chemicals spanning a range of physicochemical properties in various in vitro (carcinogenicity) assays over
time, the dependence of the observed effect concentration on non-specific
binding, exposure and recovery time, cell concentration and type, metabolism,
evaporation, degradation, and the chemical’s mechanism of action are be
deduced. Such dependence sheds light onto whether physiologically based
biokinetic (PBBK) models translating toxic potencies determined in in vitro assays to equivalent acute and
chronic toxic doses in humans are best parameterized using in vitro effect concentrations expressed as nominal concentrations,
initial free concentrations, free concentrations at the end of the exposure
period, the geometric mean of free concentrations over time, maximum or peak
concentrations in the cell, ‘critical cell burdens’ (analogous to critical body
residues, CBR), or the area under a curve (AUC, concentration in cells over
time). - The role of facilitated transport by serum
protein in in vitro intrinsic
clearance
When a chemical is
exposed to an in vitro cell assay in
culture medium with serum protein, the effect (e.g. clearance) observed may be
lower than when the chemical is exposed in culture medium without serum
protein. This is because the chemical can bind to serum protein, which reduces
the unbound free concentration of the chemical available for uptake into cells.
Therefore, it is better to determine in
vitro intrinsic clearance (CLint) based on unbound fractions of chemicals.
However, serum protein may also facilitate the transport of chemicals through
aqueous media (facilitated transport). Thus the presence of serum protein may
increase the uptake rate of chemicals into cells and solid phase
microextraction (SPME) fibers. If the uptake rate determines clearance, then
the presence of serum protein may increase clearance, thus hampering the
extrapolation of in vitro CLint to in vivo clearance when clearance assays
use varying concentrations of serum. Therefore, the uptake rate and clearance
of chemicals strongly and weakly bound to albumin, and chemicals slowly and
quickly cleared in vitro is measured
in a number of in vitro clearance
assays (including HepaRG, HepG2 and H4IIE hepatoma cell lines) at varying
concentrations of bovine serum albumin using the substrate depletion approach.
To measure the free fraction, mimic uptake of these chemicals in cells, and
facilitate the modeling of the transport into cells, SPME is used to extract
the unbound chemical from the exposure medium. - The development of in vitro assays to test for sex
steroid hormone production interference
Sex steroidogenesis (i.e. CYP17 and CYP19/aromatase enzyme
activity) is a target for endocrine disrupting compounds (EDCs) which by their
action can disrupt the hormonal balance in humans and other organisms thus
resulting in reproductive toxicity. This project aims at developing in vitro alternative (screening) methods
for EDCs, more specifically directed towards identifying effects on
steroidogenesis and spermatogenesis. At first, a comparison of a new model
using porcine adrenal cortex microsomes (PACMs) for assessing effects on CYP17,
the enzyme responsible for formation of DHEA, the most abundant circulating
steroid in the human body, was evaluated and compared with the H295R cell
steroidogenesis assay and the human placental microsomes (HPMs) assay for CYP19
activity (Roelofs et al, 2013). Next,
our research focused at the topic of male fertility. We are currently
investigating the influence of the conazoles fungicides on their ability to
activate the androgen receptor (AR) via the T47D-ARE cell line and their
effects on steroidogenesis in the MA-10 and TM3 mouse Leydig cell lines.
Furthermore, a collaboration with the department of Pharmacology and Toxicology
of the Radboud University Nijmegen Medical Centre (RUNMC) was established. This
resulted in an in vitro study using
MA-10 cells and HEK293 cells overexpressing specific ABC transporters to study
the effect of six suggested EDCs (i.e.
BPA, TBBPA, DEHP, MEHP, PFOA, and PFOS) on androgen secretion by Leydig cells
and the influence of ABC transporters on this process. In the near future
several suggested EDCs (e.g.
conazoles fungicides) will be examined with the different in vitro models to get more insight in the mechanism of their
endocrine disrupting properties. - The development of in vitro models to study the
hypothalamus pituitary gonadal (HPG) axis
The project aims to investigate the available in vitro models of hypothalamus
pituitary gonadal (HPG) axis to study the mechanisms of action and the effects
of environmental endocrine disrupting compounds on this system. The main focus
was put on female HPG axis. The in vitro
models include: available rat and human cell lines as well as rat and porcine primary cultures (purchased
from slaughterhouse). Testing compounds include: dioxins and non-dioxin like
compounds, estrogenic / antiestrogenic
like compounds (phthalates, phytoestrogens). Achievements: new rat
hypothalamic GnV-3 cell line was evaluated in the scope of the involvement of
Aryl hydrocarbon receptor (Ahr) in the regulation of important
neuroendocrinological processes in the hypothalamus (circadian rhythm, GnRH
release, food intake). Additionally, the adverse effects of dioxin and
non-dioxin like compounds was evaluated at hypothalamus, pituitary and ovarian
level using rat primary cultures. Moreover, human granulosa like tumor cell
line KGN was used to study the effects of
several groups of phytoestrogens (8-prenylnaringenin, quercetin,
resveratrol, coumestrol, genistein) on the microenviromental modulation of
granulose type tumor. Finally, the effects of estrogenic like compounds
(phytoestrogens and phthalates) are investigated on the in vitro maturation of cumulus cells and oocytes using primary
porcine oocytes. Furthermore, the possible effects of those compounds on embryo
development will be elucidated.
- An in vitro
model to study the regulation of alkaline phosphatase induction in the
liver
The enzyme alkaline
phosphatase (AP) regulates inflammatory immune responses by dephosphorylating
extracellular nucleotides and lipopolysaccharides (LPS). Several isoenzymes of
AP exist of which the liver type AP is the most abundant tissue non-specific
type. Upon a pro-inflammatory stimulus, AP is released from liver into the
circulation and quickly cleared by Kupffer cells after dephosphorylating LPS.
Clinically, it has been shown that endogenous AP was induced in open-heart
surgery patients treated with a bolus and a subsequent infusion of supplemental
AP during surgery, thus reducing the risk of systemic inflammatory response
syndrome (SIRS). The aim of this study is to develop an in vitro assay to study the mechanism of AP induction in the liver
and its release from the cells after an inflammatory insult. An insight into the
mechanism should improve the search for drugs and techniques to prolong the
residence time of AP in the bloodstream of patients with, for example,
rheumatism and a high risk of SIRS. The mRNA expression and activity of AP in
the human hepatocarcinoma cell lines, HepaRG and HepG2, as well as the
osteoblast-like cell line, Saos-2, are measured after LPS stimulation under
various (co-)culture conditions.
- The effect of the displacement of chemicals from
serum constituents on in vitro mixture
toxicity
In
vitro assays may be used to estimate toxicity of mixtures of chemicals. The
concentrations of chemicals in these assays are normally expressed as nominal
concentrations. However, the freely available concentration may be much lower
than the nominal concentration because the chemical may bind to serum
constituents in the culture medium. When chemicals are exposed to an in vitro assay in a mixture, one
chemical that is normally bound to serum protein (and thus has a low free
concentration) may be displaced from serum protein by another chemical that
binds more strongly to protein, thus increasing the free concentration and
response of the first chemical in the assay. When nominal concentrations are
used, one could falsely attribute this increase in response as being a direct
effect of the second chemical. Therefore, the aim of this study is to measure
the free concentration of a number of organic chemicals individually and in a
mixture, in a CAFLUX and a basal cytotoxicity assay, using solid phase
microextraction (SPME).
- Data on
in vitro metabolism and
mechanisms of action in combination with kinetic modeling: integrating in
risk assessment
This project is being carried out in the framework of
a CEFIC LRI project, which is conducted in cooperation with The Hamner Institutes
in Research Triangle Park (NC, USA), the Dutch National Institute of Health and
the Environment (RIVM, Bilthoven, NL) and KWR Water Research Institute (Nieuwegein,
NL). In this study an approach was developed for the
integration of in silico and in vitro
derived toxicity data in human risk assessment. The first part of the project
was focusing on selecting a set of compounds for which there are reliable in vivo toxicity data available. For
these compounds we used a number of in silico systems (DEREK, OECD-Toolbox,
TOPKAT) to predict toxicity endpoints and targets in vivo. In silico systems to predict the formation of metabolites
(METEOR, OECD-Toolbox) were used and added to the prediction for toxicity
endpoints and targets. The outcomes were compared with known in vivo toxicity endpoints and targets.
A main conclusion was that a generally good qualitative prediction was
possible, with some drawbacks that can be related to the underrepresentation of
certain endpoints in the in silico systems (e.g. neurotoxicity). The addition
of biotransformation predictions further improved the qualitative predictions. Part 2 used the qualitative predictions made in part 1 in selecting appropriate in vitro systems that could be used to
obtain toxic concentrations for the endpoints and targets. This was mainly done
on the basis of date derived from studies found in the literature, and
preference was given to data derived from those studies that used
well-established in vitro systems. In part 3, kinetic modelling was used to evaluate
steady-state blood concentrations of the
compounds in this study, related to no-effect levels in vivo. This was done based on in vivo and on in vitro data. The results were very comparable in the majority of
the cases. In the final part 4 of the project we used the in vitro-obtained toxicity data (from
part 2) as points of departure to predict in
vivo toxic doses, making use of reverse dosimetry based on the kinetic
modelling done in part 3. The outcome was then compared with known in vivo human safe doses. The result
showed that in general the in vitro-derived
evaluations for human risk underestimated the in vivo toxicity. In over half the cases studied here, however, the
ratio between the in vitro and the in vivo derived risk estimates differed
no more than two orders of magnitude. Important reasons for the underestimations are the
apparent lack of relevant biotransformation processes in the in vitro systems as well as the lack of
detailed data on in vitro biokinetic
behaviour of the compounds under study. Overall we conclude that the QIVIVE approach proposed
here to integrate in silico- and in vitro-derived
toxicity data needs refinements, mainly by improving our knowledge of the
relevant biotransformation processes and how to incorporate them in in vitro systems. In general, however,
qualitative predictions of endpoints was good; the quantification very much
depends on the quality of the in vitro
data for their relevance to qualitatively predict in vivo toxicity more precisely.
- Profiling the toxicity of new drugs: a non
animal-based approach integrating toxico-dynamics and biokinetics
Improvement of the applicability of in vitro methods by better understanding
the biokinetics of a compound within the in
vitro systems, i.e. “biokinetics in
vitro”. This is the major component
of the work at IRAS in relation to the EU-framework FP7programme Predict-IV. By
studying the processes that determine the real (free) concentration
(evaporation, binding to plastic and to medium proteins) we were able to
improve the possibilities to interpret the toxicity of compounds. This was done
by developing and implementing methods to determine the free concentration of
compounds by means of solid-phase microextraction (SPME) methods. This was done
in 3T3 cells, fish cell lines (as part of other programmes) as well as in the
Caco-2 system for measuring transport over a gastrointestinal epithelium layer.
|